atai Life Sciences Reports First Quarter 2022 Financial Results and Business Update

atai Life Sciences Reports First Quarter 2022 Financial Results and Business Update

atai Life Sciences (ATAI) announced Q1 highlights including a $36.9M net loss and $335M in cash, which is projected to fund operations until the end of 2023. The company plans to progress 10 compounds through clinical development, which are supported by a total of 171 issued patents and 49 pending patents.

PDF of article